MCID: ACT008
MIFTS: 54

Actinic Keratosis

Categories: Cancer diseases, Genetic diseases, Skin diseases

Aliases & Classifications for Actinic Keratosis

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 12 76 55 15 73
Senile Hyperkeratosis 12
Seborrheic Keratosis 73
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 44
Solar Keratosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8866
ICD10 33 L57.0
ICD9CM 35 702.0
MeSH 44 D055623
NCIt 50 C3148
SNOMED-CT 68 46795000 856006

Summaries for Actinic Keratosis

MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to squamous cell carcinoma and bowen's disease. An important gene associated with Actinic Keratosis is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Mitotic G1-G1/S phases and MicroRNAs in cancer. The drugs Picato gel and Aminolevulinic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are growth/size/body region and behavior/neurological

Wikipedia : 76 Actinic keratosis (AK) is a pre-cancerous patch of thick, scaly, or crusty skin. These growths are more... more...

Related Diseases for Actinic Keratosis

Diseases in the Actinic Keratosis family:

Keratosis, Familial Actinic

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.4 CDKN2A MMP2 PTGS2 TP53 TP63
2 bowen's disease 31.1 KRT17 PCNA
3 in situ carcinoma 30.6 CDKN2A KRT17 TP53
4 basal cell carcinoma 30.6 CDKN2A KRT17 KRT20 MC1R TP53 TP63
5 keratoacanthoma 30.2 FLG KRT17 TP53
6 papilloma 29.5 CDKN2A FLG KRT20 PCNA TP53 TP63
7 keratosis 11.9
8 actinic cheilitis 11.4
9 basal cell carcinoma 1 10.7
10 melanoma 10.5
11 bladder squamous cell carcinoma 10.3 CDKN2A TP53
12 protoplasmic astrocytoma 10.3 PTGS2 TP53
13 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
14 spitz nevus 10.3 CDKN2A TP53
15 multicentric osteolysis, nodulosis, and arthropathy 10.3 MMP14 MMP2
16 winchester syndrome 10.3 MMP14 MMP2
17 bladder carcinoma in situ 10.2 CDKN2A TP53
18 scrotal carcinoma 10.2 CDKN2A TP53
19 bizarre leiomyoma 10.2 CDKN2A PCNA
20 colloid adenoma 10.2 KRT20 TP53
21 vulvar disease 10.2 CDKN2A TP53
22 fibroepithelial basal cell carcinoma 10.2 KRT20 TP53
23 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
24 arteriovenous fistula 10.2 MMP2 PCNA
25 bladder papillary transitional cell neoplasm 10.2 KRT20 TP53
26 bartholin's gland disease 10.2 CDKN2A TP53
27 urinary tract papillary transitional cell benign neoplasm 10.2 KRT20 TP53
28 psoriasis 10.2
29 vulval paget's disease 10.2 CDKN2A KRT20
30 anal squamous cell carcinoma 10.2 CDKN2A TP53
31 bile duct adenoma 10.2 CDKN2A KRT20
32 balanitis xerotica obliterans 10.2 CDKN2A PTGS2
33 ameloblastic carcinoma 10.2 CDKN2A TP63
34 tongue disease 10.2 CDKN2A MMP2 TP53
35 laryngeal disease 10.2 CDKN2A MMP2 TP53
36 supratentorial cancer 10.2 CDKN2A MMP2 TP53
37 megaesophagus 10.2 CDKN2A TP53
38 cerebrum cancer 10.2 CDKN2A MMP2 TP53
39 barrett's adenocarcinoma 10.2 CDKN2A PTGS2 TP53
40 skin melanoma 10.2 CDKN2A MMP2 TP53
41 esophageal disease 10.2 CDKN2A PTGS2 TP53
42 cornea cancer 10.2 CDKN2A TP63
43 juvenile pilocytic astrocytoma 10.2 CDKN2A TNC TP53
44 cystic basal cell carcinoma 10.2 KRT20 TP63
45 tongue cancer 10.2 CDKN2A MMP2 TP53
46 papillary serous adenocarcinoma 10.2 KRT20 TP53
47 female reproductive system disease 10.2 CDKN2A MMP2 TP53
48 respiratory system cancer 10.2 CDKN2A MMP2 TP53
49 tongue squamous cell carcinoma 10.2 CDKN2A MMP2 TP53
50 endocrine gland cancer 10.2 CDKN2A MMP2 TP53

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis

Symptoms & Phenotypes for Actinic Keratosis

MGI Mouse Phenotypes related to Actinic Keratosis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 CDKN2A KRT17 LUM MC1R MCM2 MMP14
2 behavior/neurological MP:0005386 10.21 CDKN2A LUM MC1R MCM2 MMP14 PTGS2
3 cellular MP:0005384 10.2 CDKN2A KRT17 LUM MC1R MCM2 MMP14
4 immune system MP:0005387 10.18 CDKN2A LUM MC1R MCM2 MMP14 MMP2
5 hematopoietic system MP:0005397 10.15 CDKN2A LUM MC1R MCM2 MMP14 MMP2
6 digestive/alimentary MP:0005381 10.13 CDKN2A KRT17 LUM MCM2 MMP14 PTGS2
7 mortality/aging MP:0010768 10.13 CDKN2A KRT17 LUM MCM2 MMP14 MMP2
8 integument MP:0010771 10.11 CDKN2A KRT17 LUM MC1R MCM2 MMP14
9 craniofacial MP:0005382 10.01 KRT17 MC1R MMP14 MMP2 TP53 TP63
10 muscle MP:0005369 10.01 CDKN2A LUM MCM2 MMP14 MMP2 PTGS2
11 no phenotypic analysis MP:0003012 9.97 CDKN2A KRT17 MC1R MMP14 PCNA PTGS2
12 neoplasm MP:0002006 9.91 CDKN2A MC1R MCM2 MMP2 PTGS2 TP53
13 normal MP:0002873 9.8 MCM2 MMP14 MMP2 PTGS2 TNC TP53
14 pigmentation MP:0001186 9.55 CDKN2A KRT17 MC1R MCM2 TP53
15 respiratory system MP:0005388 9.5 CDKN2A MCM2 MMP14 MMP2 PTGS2 TP53
16 vision/eye MP:0005391 9.17 CDKN2A LUM MMP14 MMP2 PTGS2 TP53

Drugs & Therapeutics for Actinic Keratosis

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Picato gel 18 INGENOL MEBUTATE LEO Pharma January 2012

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 51-21-8 3385
4
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
5
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 15307-86-5 3033
6
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
7
Alginic acid Approved, Investigational Phase 4 9005-32-7
8
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
9
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
10
Petrolatum Approved, Investigational Phase 4,Phase 2,Early Phase 1,Not Applicable 8009-03-8
11
Hydrogen peroxide Approved, Vet_approved Phase 4,Phase 2 7722-84-1 784
12
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-72-7 338
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
15
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
16
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
17
Menthol Approved Phase 4 2216-51-5 16666
18
Azathioprine Approved Phase 4 446-86-6 2265
19
Mycophenolic acid Approved Phase 4 24280-93-1 446541
20
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
21
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
22
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
24 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Radiation-Protective Agents Phase 4,Phase 2
32 Sunscreening Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
36 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1,Not Applicable
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Vitamins Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Keratolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Viscosupplements Phase 4
47 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Retinol palmitate Phase 4,Phase 3,Phase 2
50 retinol Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 367)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
5 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
6 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
7 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
8 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
9 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
10 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
11 Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
12 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
13 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
14 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
15 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
16 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
17 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
18 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
19 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
20 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
21 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
22 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
23 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
24 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
25 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
26 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
27 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
28 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
29 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
30 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
31 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
32 Treatment of Photodamaged Skin of the décolleté Recruiting NCT03573076 Phase 4
33 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
34 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
35 An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Active, not recruiting NCT03487588 Phase 4 A-101 Topical Solution
36 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
37 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
38 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention Not yet recruiting NCT03642535 Phase 4 ALA
39 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
40 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
41 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
42 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
43 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
44 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
45 Actinic Keratoses Treatment With Metvix® in Combination With Light Unknown status NCT02373371 Phase 3 Metvix®
46 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
47 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
48 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
49 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00942604 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
50 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00742391 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Genetic Tests for Actinic Keratosis

Anatomical Context for Actinic Keratosis

MalaCards organs/tissues related to Actinic Keratosis:

41
Skin, Testes, Bone, Breast, Kidney, Lung, Liver

Publications for Actinic Keratosis

Articles related to Actinic Keratosis:

(show top 50) (show all 845)
# Title Authors Year
1
Efficacy Endpoints in Clinical Trials in Actinic Keratosis. ( 29916197 )
2018
2
Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. ( 29779986 )
2018
3
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. ( 29620004 )
2018
4
Comparison of 10 efficient protocols for photodynamic therapy of actinic keratosis: How relevant are effective light dose and local damage in predicting the complete response rate at 3 months? ( 29667728 )
2018
5
Reflectance confocal microscopy: a crucial role for actinic keratosis treatment monitoring. ( 29846971 )
2018
6
Successful Treatment of Actinic Keratosis with Kanuka Honey. ( 29955399 )
2018
7
A multi-centre, open, investigator initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). ( 29355904 )
2018
8
Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. ( 29920789 )
2018
9
MART-1-Labeled Melanocyte Density and Distribution in Actinic Keratosis and Squamous Cell Cancer in situ: Pagetoid Melanocytes are a Potential Source of Misdiagnosis as Melanoma in Situ. ( 29943494 )
2018
10
Differential proteomic analysis of actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma by label-free LC-MS/MS. ( 29665991 )
2018
11
Treatment of Grade II and III Actinic Keratosis Lesions with a Film-Forming Medical Device Containing Sunscreen/Piroxicam 0.8% and a Retinoic Acid/Glycolic Gel: A Pilot Trial. ( 29855896 )
2018
12
Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation. ( 29407554 )
2018
13
Photodynamic therapy with the use of superluminescent diodes (sLED) in the treatment of actinic keratosis. ( 29684690 )
2018
14
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up. ( 29441544 )
2018
15
Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. ( 29351725 )
2018
16
Energy-based devices for actinic keratosis field therapy. ( 29894524 )
2018
17
Teledermatology-driven topical therapy of actinic keratosis: a comparative study of clinical effectiveness and compliance. ( 29797670 )
2018
18
Swiss (German) Version of the Actinic Keratosis Quality of Life questionnaire. ( 29669340 )
2018
19
Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). ( 29909413 )
2018
20
Daylight Photodynamic Therapy Versus 5-Fluorouracil for the Treatment of Actinic Keratosis: A Case Series. ( 29322431 )
2018
21
Treatment of Actinic Keratosis with Photodynamic Therapy Using Red or Green Light: A Comparative Study. ( 29963684 )
2018
22
Field-change actinic keratosis and immunosuppression: therapeutic options. ( 29668097 )
2018
23
Effectiveness and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of actinic keratosis and skin field cancerisation of the forearms: a randomized controlled trial. ( 29862491 )
2018
24
Detection of human papillomavirus in actinic keratosis. ( 29383738 )
2018
25
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. ( 29442526 )
2018
26
Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. ( 29316678 )
2018
27
Daylight photodynamic therapy: experience in the treatment of actinic keratosis in San Gallicano Institute of Rome and a review of literature. ( 29368865 )
2018
28
Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response. ( 29356164 )
2018
29
Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index. ( 29791916 )
2018
30
Effect of ingenol mebutate on actinic keratosis in a Korean population: A prospective clinical, dermoscopic and histopathological study from a single center. ( 30260493 )
2018
31
Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. ( 30267719 )
2018
32
Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions. ( 30288788 )
2018
33
A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes. ( 30301852 )
2018
34
Full face ingenol mebutate for actinic keratosis: patient perspective. ( 30302750 )
2018
35
Conjunctival actinic keratosis. ( 30314825 )
2018
36
Claudin-1 expression decreases with increasing pathological grade in actinic keratosis and may be a marker of high-risk actinic keratosis. ( 30315595 )
2018
37
Monitoring treatment response in patients affected by actinic keratosis: Dermoscopic assessment and metalloproteinases evaluation after piroxicam 0.8% and sunfilter cream. ( 30318747 )
2018
38
Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice. ( 30323610 )
2018
39
Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015. ( 30326488 )
2018
40
5-aminolevulinic acid nanoemulsion (BF-200 ALA) is more effective than methyl-5-aminolevulinate (MAL) in daylight photodynamic therapy for actinic keratosis: A non-sponsored randomized double-blind multicentre trial. ( 30329163 )
2018
41
Conventional versus daylight photodynamic therapy for actinic keratosis: A randomized and prospective study in China. ( 30336290 )
2018
42
Effects of topical 0.8% piroxicam and 50+ sunscreen filters on actinic keratosis in hypertensive patients treated with or without photosensitizing diuretic drugs: an observational cohort study. ( 30349346 )
2018
43
Dynamic thermal imaging on actinic keratosis patients: A preliminary study. ( 30357926 )
2018
44
Photodynamic therapy for actinic keratosis of the forehead and scalp: a randomized, controlled, phase II clinical study evaluating the non-inferiority of a new protocol involving irradiation with a light-emitting, fabric-based device (the Flexitheralight protocol) compared with the conventional protocol involving irradiation with the Aktilite CL 128 lamp. ( 30367470 )
2018
45
Immunological effects of photodynamic therapy in the treatment of actinic keratosis and squamous cell carcinoma. ( 30381259 )
2018
46
Efficacy of different photoprotection strategies in preventing actinic keratosis new lesions after photodynamic therapy. The ATHENA study: a two-center, randomized, prospective, assessor-blinded pragmatic trial. ( 30404544 )
2018
47
Daylight versus conventional photodynamic therapy for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. ( 30412779 )
2018
48
Anti-aging effects of ingenol mebutate for patients with actinic keratosis. ( 30420007 )
2018
49
Photodynamic therapy activated by intense pulsed light in the treatment of actinic keratosis. ( 30428649 )
2018
50
Cryosurgery combined with topical interventions for actinic keratosis: A systematic review and meta-analysis. ( 30447074 )
2018

Variations for Actinic Keratosis

Expression for Actinic Keratosis

Search GEO for disease gene expression data for Actinic Keratosis.

Pathways for Actinic Keratosis

GO Terms for Actinic Keratosis

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.26 LUM MMP14 MMP2 TNC
2 collagen-containing extracellular matrix GO:0062023 8.92 FLG LUM MMP2 TNC

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.58 LUM MMP14 PTGS2
2 apoptotic process GO:0006915 9.55 CDKN2A KRT20 MCM2 TP53 TP63
3 response to oxidative stress GO:0006979 9.54 MMP14 PCNA PTGS2
4 establishment of skin barrier GO:0061436 9.43 FLG TP63
5 cornification GO:0070268 9.43 FLG KRT17 KRT20
6 intermediate filament organization GO:0045109 9.32 KRT17 KRT20
7 replicative senescence GO:0090399 8.96 CDKN2A TP53
8 cellular response to UV GO:0034644 8.8 PCNA PTGS2 TP53

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.5 CDKN2A FLG KRT17 KRT20 LUM MC1R
2 enzyme binding GO:0019899 9.26 MCM2 PCNA PTGS2 TP53

Sources for Actinic Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....